Stock Screener
US stocks rated by the Lician Quant model: a 1–5 rating and A+ to F grades for valuation, growth, profitability, momentum and EPS revisions, each against the stock’s sector. Filter, sort by any factor and share the URL.
51 stocks · Strong Buy or Buy · Healthcare · Growth ≥ A-
| Stock | Quant ratingRating | ValuationVal | GrowthGrow | ProfitabilityProf | MomentumMom | EPS revisionsRev | Market capMkt cap | P/EP/E | Revenue growthRev YoY | Div. yieldYield | Short % floatShort | Next earningsEarnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1AVAHAveanna Healthcare Holdings Inc | 4.99Strong Buy | A | A- | B+ | A | A+ | $2.9B | 10.6 | +19.5% | — | 10.2% | Nov 12 |
| 2OSCROscar Health Inc | 4.97Strong Buy | — | A | A- | A | B- | — | — | +42.8% | — | — | Nov 5 |
| 3BTSGBrightSpring Health Services, Inc. Common Stock | 4.96Strong Buy | A- | A- | B- | A | — | $11.6B | 28.4 | +22.9% | — | 12.0% | — |
| 4PACSPACS Group, Inc. | 4.94Strong Buy | B+ | A | A- | A | B | $7.6B | 28.1 | +16.6% | — | — | — |
| 5ASTHAstrana Health Inc | 4.93Strong Buy | A+ | A | B | C | A+ | $1.8B | 44.0 | +58.9% | — | 8.0% | Nov 5 |
| 6ARQTArcutis Biotherapeutics Inc | 4.92Strong Buy | C+ | A+ | A- | A- | B+ | $3.9B | 137.4 | +76.1% | — | 23.9% | Nov 4 |
| 7GMEDGlobus Medical | 4.91Strong Buy | A+ | A- | A | C | A- | $8.6B | 16.1 | +19.7% | — | 7.3% | Nov 5 |
| 8NUTXNutex Health Inc | 4.90Strong Buy | A+ | A- | A | B- | B- | $1.4B | 7.3 | +6.9% | — | — | Nov 5 |
| 9KNSAKiniksa Pharmaceuticals Ltd | 4.89Strong Buy | B- | A+ | A | A+ | C | $4.1B | 37.7 | +58.2% | — | 9.6% | — |
| 10PTGXProtagonist Therapeutics Inc | 4.88Strong Buy | C | A- | A+ | B+ | A | $9.4B | 113.0 | +34.8% | — | — | Nov 5 |
| 11NBIXNeurocrine Biosciences Inc | 4.87Strong Buy | B+ | A | A+ | B- | B | $14.7B | 21.0 | +38.0% | — | 6.6% | — |
| 12MGTXMeiraGTx Holdings PLC | 4.82Strong Buy | A | A+ | A+ | D | B- | $897M | 11.4 | +948.3% | — | 17.6% | Nov 12 |
| 13ETONEton Pharmaceuticals Inc | 4.80Strong Buy | D+ | A+ | A- | A- | A- | $1.4B | 113.6 | +81.5% | — | 9.3% | Nov 5 |
| 14CRONCronos Group Inc | 4.80Strong Buy | A | A- | B+ | B+ | B- | $1.2B | 17.6 | +37.5% | — | 1.9% | Nov 5 |
| 15PDEXPro-Dex Inc | 4.79Strong Buy | A | A- | B+ | C+ | A- | $184M | 13.4 | +16.5% | — | 13.0% | — |
| 16SNYSanofi | 4.77Strong Buy | — | A- | A | C+ | — | — | — | — | — | — | — |
| 17ACADACADIA Pharmaceuticals Inc | 4.75Strong Buy | A | A- | A+ | D | B+ | $3.3B | 8.7 | +11.8% | — | 7.9% | Nov 4 |
| 18DCTHDelcath Systems Inc | 4.73Strong Buy | C+ | A+ | B | B | A- | $499M | 938.8 | +35.8% | — | 6.6% | Nov 9 |
| 19AUPHAurinia Pharmaceuticals Inc | 4.71Strong Buy | B+ | A | A+ | B- | D+ | $2.1B | 6.8 | +21.0% | — | 5.9% | — |
| 20ANIPANI Pharmaceuticals Inc | 4.67Strong Buy | A+ | A | A | D | C+ | $1.6B | 14.8 | +30.9% | — | 22.7% | Nov 5 |
| 21LLYEli Lilly and Company | 4.65Strong Buy | — | A | A+ | A+ | F | — | — | +45.5% | 0.56% | — | — |
| 22ZVRAZevra Therapeutics Inc. | 4.59Strong Buy | A- | A+ | A+ | C | D+ | $582M | 10.0 | +119.4% | — | — | — |
| 23PHRPhreesia Inc | 4.58Strong Buy | A+ | A- | B | B- | C | $748M | 71.6 | +12.9% | — | 5.4% | Dec 14 |
| 24VCYTVeracyte Inc | 4.55Strong Buy | B+ | A- | A | A- | D- | $3.5B | 30.3 | +17.3% | — | — | Nov 4 |
| 25GRALGRAIL, LLC | 4.48Buy | D+ | A- | D+ | A | A+ | $5.6B | NM | +23.1% | — | 24.4% | Nov 4 |
Showing 25 of 51
Source: Lician Quant Grades (SEC EDGAR statements, EODHD prices and estimates); short interest: FINRA; earnings dates: earnings calendar; dividend yield: EODHD fundamentals · Quant run Nov 4, 2026
Grades rank each stock against its sector peers; they are not investment advice. How the rating and grades work · Short interest · Earnings calendar